The groundbreaking success of the copyright undeniably transformed the drug landscape, but investing in companies heavily reliant on unbranded versions presents a challenging picture. Despite early returns were substantial, the expiration of patents and the rise of discounted alternatives have diminished sales. Therefore, a thorough analysis of ong